{"public_id":"cl_cb268e3ad958af1af645d8d73e0a0634","status":"active","superseded_by_public_id":null,"corpus_id":251478343,"text":"Brolucizumab appears promising for more challenging maculopathies such as diabetic macular oedema.","confidence":0.78,"paper":{"corpus_id":251478343,"title":"Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies","url":"https://sah.borca.ai/papers/251478343"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.78,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_0e0b142aa73ed09b282db564e9505bca","name":"diabetic macular oedema","description":"Macular swelling caused by diabetic retinal vascular disease.","types":["disease"],"url":"https://sah.borca.ai/concepts/co_0e0b142aa73ed09b282db564e9505bca"},{"public_id":"co_f0cd768b2c5a15aef8dd6b7f178acb62","name":"maculopathies","description":"Diseases affecting the macula, the central region of the retina responsible for detailed vision.","types":["disease category"],"url":"https://sah.borca.ai/concepts/co_f0cd768b2c5a15aef8dd6b7f178acb62"},{"public_id":"co_f9a425cd4e805f76e9e439e1d02ca988","name":"brolucizumab","description":"A humanized single-chain antibody fragment that binds VEGF-A and is used by intravitreal injection for retinal disease.","types":["drug","therapeutic agent"],"url":"https://sah.borca.ai/concepts/co_f9a425cd4e805f76e9e439e1d02ca988"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_cb268e3ad958af1af645d8d73e0a0634"}